tanshinone ii a has been researched along with Dihydrotanshinone I in 11 studies
| Studies (tanshinone ii a) | Trials (tanshinone ii a) | Recent Studies (post-2010) (tanshinone ii a) | Studies (Dihydrotanshinone I) | Trials (Dihydrotanshinone I) | Recent Studies (post-2010) (Dihydrotanshinone I) |
|---|---|---|---|---|---|
| 61 | 0 | 41 | 88 | 0 | 74 |
| Protein | Taxonomy | tanshinone ii a (IC50) | Dihydrotanshinone I (IC50) |
|---|---|---|---|
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 3.05 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.59 | |
| Acetylcholinesterase | Homo sapiens (human) | 1 | |
| Tyrosine-protein phosphatase non-receptor type 6 | Homo sapiens (human) | 3.67 | |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 3.94 | |
| ELAV-like protein 1 | Homo sapiens (human) | 0.1085 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 2.17 | |
| Endothelial PAS domain-containing protein 1 | Homo sapiens (human) | 2.17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Dat, NT; Hong, YS; Jin, X; Kim, YH; Lee, D; Lee, JH; Lee, JJ; Lee, K | 1 |
| Cheung, CC; Fung, KP; Lai, PB; Lee, WY; Liu, KW; Wong, J; Yeung, JH | 1 |
| Jeong, HJ; Kim, DW; Kim, JH; Kim, YM; Kwon, HJ; Lee, WS; Park, JY; Park, KH; Park, SJ; Ryu, YB | 1 |
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Edwards, CC; Hatfield, MJ; Hyatt, JL; Jeffries, C; Lemoff, A; Potter, PM; Tsurkan, LG; Yan, B | 1 |
| Liu, W; Loh, ML; Qu, CK; Tang, LD; Xu, G; Xu, WR; Yu, B | 1 |
| Cheung, J; Gary, EN; Rosenberry, TL; Shiomi, K | 1 |
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
| Hu, Y; Jadhav, P; Tan, B; Tan, H; Wang, J | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
1 review(s) available for tanshinone ii a and Dihydrotanshinone I
| Article | Year |
|---|---|
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
Topics: Antiviral Agents; Coronavirus Papain-Like Proteases; COVID-19 Drug Treatment; Humans; Pandemics; Protease Inhibitors; SARS-CoV-2 | 2022 |
10 other study(ies) available for tanshinone ii a and Dihydrotanshinone I
| Article | Year |
|---|---|
Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1.
Topics: Abietanes; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Humans; Hypoxia-Inducible Factor 1; Korea; Plants, Medicinal; Salvia miltiorrhiza; Tumor Cells, Cultured | 2007 |
Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells.
Topics: Abietanes; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Doxorubicin; Drug Resistance, Neoplasm; Humans; Models, Biological; Molecular Structure; Phenanthrenes; Plants, Medicinal; Salvia miltiorrhiza | 2010 |
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.
Topics: Abietanes; Cysteine Proteinase Inhibitors; Humans; Kinetics; Protein Binding; Salvia miltiorrhiza; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Ubiquitination | 2012 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").
Topics: Abietanes; Algorithms; Camptothecin; Carboxylesterase; Clinical Trials, Phase I as Topic; Drugs, Chinese Herbal; Herb-Drug Interactions; Humans; Irinotecan; Medicine, Chinese Traditional; Molecular Structure; Phenanthrolines; Plant Roots; Salvia miltiorrhiza | 2013 |
Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).
Topics: Animals; Catalytic Domain; Cell Line, Tumor; Computer-Aided Design; Drug Evaluation, Preclinical; Enzyme Activation; Enzyme Inhibitors; Humans; Mice; Models, Molecular; Mutation; Phenanthrenes; Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 2013 |
Structures of human acetylcholinesterase bound to dihydrotanshinone I and territrem B show peripheral site flexibility.
Topics: | 2013 |
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |